Cannabinoid Biosciences Pitch Deck: 15-Slide Breakdown

Cannabinoid Biosciences (CBDZ) presents a pitch deck centered on a massive $125 million capital raise intended to fund a biopharmaceutical R&D arm alongside a retail rollup of at least 10 cannabis dispensaries. The core thesis relies on a valuation arbitrage play: acquiring private cannabis businesses at roughly 2x revenue and rolling them into a public entity that the company claims could be valued at over 100x revenue based on then-current market peers like Aurora Cannabis and Cronos Group. While the deck provides specific financial targets for 20 acquisition candidates, it lacks a formal t…

Key takeaways

• The company is seeking a total of $125 million, split between a $50 million Regulation A+ offering and a $75 million Regulation D 506(c) offering (Slide 7).
• The investment vehicle is a Secured Convertible Note paying 12% annual interest, convertible into shares at $10 per share (Slide 7).
• A core business pillar is 'Professional Services,' offering SEC reporting, GAAP/IFRS conversion, and 280E tax services to other cannabis businesses (Slide 3).
• The deck identifies 20 specific acquisition targets with a combined revenue of $96,389,230 and net profit of $30,356,123 (Slide 11).
• Management projects a post-consolidation valuation of $7.19 billion based on a weighted average of industry multiples (Slide 11).
• The strategy relies on the '2018 Farm Bill' and subsequent federal clarifications to stabilize the regulatory environment for CBD (Slide 5).
• The company intends to pay 50% of profits back to investors as dividends while retaining the other 50% for growth (Slide 9).
• The biopharmaceutical arm claims to focus on novel therapeutics from cannabinoids for a broad range of disease areas, though specific compounds are not listed (Slide 3).

Frequently asked questions

What is the primary investment instrument being offered?

According to slide 7, Cannabinoid Biosciences is offering a Secured Convertible Note. The note pays a 12% annual interest rate. A $1,000 note is convertible into 125 shares of CBDZ Common Stock. The company notes that these shares are being registered with the SEC under Regulation A+ to be sold at a price of $10 per share.

How does the company justify its multi-billion dollar valuation projection?

The company uses a 'Multiple to Sales' arbitrage argument. Slide 11 shows they intend to acquire targets at an average multiple of 1.32x sales. They then compare this to public peers like Aurora Cannabis (98x) and Canopy Growth (106x), which averaged 115x sales at the time. They project a $7.19 billion weighted average valuation after listing on the NASDAQ or NYSE.

What are the four main pillars of the CBDZ business model?

As detailed on slide 3, the business consists of Research & Development (novel therapeutics), Investments & Consolidation (cannabis business rollups), Financial Products (asset-backed loans and mortgages for cannabis firms), and Professional Services (accounting, SEC reporting, and tax services specialized for the 280E tax code).

What specific acquisition targets has the company identified?

Slide 11 provides a line-item list of 20 targets, ranging from 'Cultivation and Dispensary' to 'Recreational Medical Cannabis.' The targets have individual revenues ranging from $720,000 to over $13.7 million. The total investment required for these 20 targets is estimated at $113 million to capture $96.3 million in revenue.

Who is leading the company according to the deck?

The deck is notably missing a dedicated 'Team' slide showcasing the full board or management. However, the final slide (Slide 15) identifies Frank I. Igwealor as the Sr. Vice President and CFO. His credentials listed include CPA, JD, MBA, CMA, CFM, and MSRM. No other personnel are mentioned in the provided slides.

Cannabinoid Biosciences pitch deck: the facts

Company

Cannabinoid Biosciences

Slides

15

Sector

Cannabis

Cannabinoid Biosciences pitch deck PDF

The full Cannabinoid Biosciences deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Cannabinoid Biosciences, Inc. (CBDXFund / CBDZ / PIFR) pitch deck was used for

This deck is the "GET IN ON THE GROUND FLOOR OF CANNABIS INVESTMENT" investor presentation for Cannabinoid Biosciences, Inc., a biopharmaceutical and cannabis roll‑up company branded as CBDXFund. It outlines a hybrid strategy: biopharmaceutical R&D on cannabinoid‑based therapeutics alongside a $125 million cannabis retail and cultivation roll‑up, with $50 million targeted via Regulation A+ and $75 million via Regulation D to acquire 10 profitable dispensaries and related operations. The deck positions the raise as pre‑IPO ground‑floor access, aiming for a subsequent listing on NASDAQ or NYSE following consolidation of assets, in the context of the 2018–2019 legal cannabis boom.

Business model: Biopharmaceutical company focused on discovery, development and commercialization of therapeutics derived from proprietary cannabinoids, cannabidiol, endocannabinoids, phytocannabinoids and synthetic cannabinoids, combined with an investment/roll‑up strategy acquiring profitable legal cannabis dispensaries and cultivation assets to consolidate and take public.

Investors

Approximately 347 individual and institutional investors participating in the CBDXFund crowdfunding campaign, contributi, GiveMePower and Kid Castle Educational identified as investors in Cannabinoid Biosciences by a third‑party company profi

Founded

2014

Round: Growth / pre‑IPO roll‑up financing via Reg A+, Reg D, and crowdfunding in the 2018–2019 period.

Year: 2019 (crowdfunding commitments and Reg A+/Reg D raise described in the deck and related materials).

Raising: Targeting a total of $125 million, split between $50 million via Regulation A+ and $75 million via Regulation D, to fund acquisition and consolidation of 10 profitable cannabis dispensaries and cultivation facilities.

Raised: Approximately $7.6 million in investment commitments reported in connection with the CBDXFund crowdfunding campaign by November 2019.

Headquarters: Los Angeles, California, United States (3699 Wilshire Boulevard, Suite 610) with prior principal offices at 370 Amapola Ave, Suite 200A, Torrance, California.

Industry: Biotechnology / Other Pharmaceuticals and Biotechnology, focused on cannabinoid-based therapeutics and cannabis investment/roll‑up.

Use of funds as presented: Acquisition of 10 profitable legal cannabis dispensaries and cultivation facilities, consolidation into a single vehicle, biopharmaceutical R&D on cannabinoid therapeutics, and preparation for a future public listing.

What happened after the Cannabinoid Biosciences, Inc. (CBDXFund / CBDZ / PIFR) deck

Following its ground‑floor cannabis investment pitch and $125 million roll‑up plan, Cannabinoid Biosciences pursued crowdfunding and later executed a reverse merger with Premier Information Management (PIFR), resulting in a publicly traded OTC vehicle rather than the initially envisioned NASDAQ or NYSE IPO.

• Company incorporated in California on May 6, 2014 as a biotechnology and specialty pharmaceutical holding firm focused o
• Launched a crowdfunding campaign around September 28, 2019 for CBDXFund and reported approximately $7.6 million in inves
• Entered into a reverse merger agreement with Premier Information Management, Inc. (OTC: PIFR), announced May 13, 2021, m

What the Cannabinoid Biosciences, Inc. (CBDXFund / CBDZ / PIFR) deck got right

• Multi‑segment hybrid business model in cannabis therapeutics and investments. Clear articulation of a hybrid business model spanning **biopharmaceutical R&D**, **investments and consolidation of legal cannabis businesses**, **financial products**, and **professional services**, providing multiple potential revenue streams and diversification.
• Accessible ground‑floor investment narrative for retail investors. Compelling ground‑floor investment framing, including low minimum investment thresholds (around $100) and use of Reg A+ and crowdfunding to allow ordinary investors to participate alongside institutional capital.
• Defined capital raise structure and roll‑up strategy. Specific capital plan outlining a **$125 million raise split between Reg A+ and Reg D** to acquire 10 profitable dispensaries and cultivation facilities, with a clear roll‑up and IPO pathway on a major exchange.
• Valuation arbitrage thesis leveraging private–public multiple gap. Strategic focus on valuation arbitrage between private acquisition prices and public market multiples in the cannabis sector, which, if executed, can create significant upside by consolidating cash‑flow‑positive assets ahead of broader institutional participation.
• Initial investor traction via crowdfunding commitments. Early traction evidenced by reported **$7.6 million in investment commitments from 347 investors** through a crowdfunding campaign, indicating market interest in the CBDXFund proposition.
• Use of multiple regulated capital‑raising and go‑public pathways. Regulatory and structural sophistication demonstrated through use of **Reg A+ and Reg D offerings** and later a **reverse merger with an OTC‑listed entity (PIFR)** to access public markets.

What could have been stronger

• Limited visibility into actual biopharmaceutical pipeline and R&D progress. The deck describes ambitious biopharmaceutical R&D activities (discovery and commercialization of cures and therapeutics from multiple classes of cannabinoids) but, based on available materials, does not provide concrete evidence of advanced drug candidates, clinical trial plans, regulatory milestones, or IP portfolio details, making the R&D segment appear aspirational relative to the specificity of the roll‑up strategy.
• High‑level description of roll‑up without detailed acquisition pipeline or integration plan. The roll‑up plan to acquire 10 profitable dispensaries and cultivation facilities for $125 million and later list on NASDAQ or NYSE is presented at a high level, without granular data on target acquisition pipeline, negotiated deal terms, integration plans, or regulatory risks in multiple state jurisdictions.
• Overly broad assertion of minimal competition in cannabis roll‑up segment. The deck’s competition slide claims effectively no competition from funds focused on roll‑ups of existing high‑margin dispensaries in California and across the U.S., despite a broader landscape of cannabis private equity, venture vehicles, and MSOs pursuing consolidation, which may cause more sophisticated investors to question this assertion.
• Aggressive valuation projections unsupported by detailed operating metrics. The presentation leans heavily on large projected post‑IPO valuations (multi‑billion‑dollar upside based on industry multiples) but does not clearly reconcile these projections with current revenue, EBITDA, or detailed operating metrics from either existing or target portfolio companies.

How an investor would read this deck

What draws attention

• Hybrid model combining **biopharmaceutical R&D** with a **cannabis retail roll‑up** is unusual, and investors will focus on whether the team has credible capabilities in both drug development and multi‑state cannabis operations.
• The **Reg A+ and Reg D dual‑raise structure** totaling $125 million for acquisition of 10 profitable dispensaries and cultivation sites is central; investors will scrutinize how realistic the raise size is relative to market appetite and company track record.
• The promised **valuation arbitrage** between private acquisition multiples and public market trading prices, with projections into the multi‑billion‑dollar range, will attract attention but also skepticism about underlying assumptions.
• Investors will pay close attention to the reported **$7.6 million in investment commitments from 347 investors** via crowdfunding as early traction, while assessing the quality and terms of that capital.
• The subsequent **reverse merger with Premier Information Management (PIFR)** provides a path to public markets that differs from the deck’s initial NASDAQ/NYSE IPO narrative, which investors will examine to understand how the strategy evolved.

Risks that stand out

• Execution risk in pursuing simultaneous **drug development and multi‑state cannabis roll‑ups**, which require very different expertise, capital timelines, and regulatory compliance regimes.
• Regulatory risk from evolving U.S. federal and state cannabis laws, including potential enforcement changes, banking constraints, and licensing issues that could impact dispensary acquisitions and operations.
• Capital‑raising risk: the plan to secure $125 million via Reg A+ and Reg D may exceed realistic market appetite for a relatively early‑stage, hybrid biopharma–cannabis roll‑up without extensive operating history or clinical data.
• Valuation risk: the deck’s reliance on aggressive public market multiples and multi‑billion‑dollar upside projections exposes investors to significant risk if market sentiment or sector valuations compress.
• Governance and dilution risk associated with crowdfunding, subsequent private raises, and the reverse merger into an OTC‑listed vehicle, which can create complex capital structures and misaligned incentives among investor cohorts.

Questions this deck invites

• What specific cannabinoid‑based drug candidates or therapeutic programs has Cannabinoid Biosciences advanced to preclinical or clinical stages, and what evidence supports their potential (data, patents, regulatory interactions)?
• What is the current and historical financial performance (revenue, EBITDA, margins) of both Cannabinoid Biosciences and any acquired or targeted dispensaries and cultivation facilities underlying the $125 million roll‑up plan?
• How did the company structure its Reg A+ and Reg D offerings (terms, share classes, rights), and how are early crowdfunding investors treated relative to later institutional capital and the reverse‑merger outcome?
• What specific dispensary and cultivation assets have been acquired or definitively contracted since this deck, and how have these assets performed operationally and financially post‑acquisition?
• How does the regulatory environment across federal, state, and local jurisdictions (including cannabis licensing, banking, and securities regulation) affect the feasibility, timing, and risk profile of the roll‑up and public listing strateg

What founders can take from the Cannabinoid Biosciences, Inc. (CBDXFund / CBDZ / PIFR) deck

• Hybrid narratives that combine a **core operating business (biopharmaceutical R&D)** with a **financial roll‑up strategy** can be compelling but must be supported by clear evidence of capabilities in both domains to avoid investor skepticism.
• Ground‑floor retail investor positioning (small minimum investments via crowdfunding, Reg A+) can help build early traction and community, yet later institutional investors will still demand robust fundamentals and transparent governance.
• Presenting a large top‑line raise (e.g., $125 million) and multi‑billion‑dollar valuation upside may capture attention, but investors expect detailed operating metrics, acquisition pipelines, and integration plans to substantiate such targets.
• Claims about limited competition in an emerging, popular sector like legal cannabis need to be carefully framed and supported by market analysis; sophisticated investors will benchmark against known private equity, MSO, and fund activity.
• Using regulated offering structures (Reg A+, Reg D) and later a reverse merger provides multiple paths to the public markets, but each path must be clearly explained to investors to manage expectations about listing venue, timing, and liquidity.
• Crowdfunding commitments (such as the reported $7.6 million from 347 investors) can serve as proof of interest, but the quality, terms, and sustainability of this capital are critical in assessing long‑term viability.

Cannabinoid Biosciences, Inc. (CBDXFund / CBDZ / PIFR) pitch deck: common questions

What is Cannabinoid Biosciences and what does it do?

Cannabinoid Biosciences, Inc. is a California‑incorporated biopharmaceutical and specialty pharmaceutical holding company focused on discovering, developing and commercializing cures and novel therapeutics from proprietary cannabinoid product platforms, while also pursuing a roll‑up of profitable CBD and cannabis operations across the United States.

How much was Cannabinoid Biosciences trying to raise in this pitch deck and for what purpose?

The deck describes a $125 million total raise split into $50 million under Regulation A+ and $75 million under Regulation D, intended to fund the acquisition and consolidation of 10 profitable legal cannabis dispensaries and cultivation facilities, followed by an IPO on NASDAQ or NYSE.

What was the core investment thesis presented in the Cannabinoid Biosciences deck?

The company’s plan was to roll up existing high‑margin dispensaries and cultivation facilities into a consolidated vehicle, extract valuation arbitrage between private acquisition multiples and public market trading prices, and ultimately list the combined operations on a major U.S. exchange, providing ground‑floor access to cannabis investments for small investors.

Did Cannabinoid Biosciences raise any money related to this fund or campaign?

Cannabinoid Biosciences launched a crowdfunding campaign around September 28, 2019, and by November 2019 reported investment commitments of about $7.6 million from approximately 347 individual and institutional investors, linked to its CBDXFund raise.

What happened to Cannabinoid Biosciences after this deck—did it go public or merge with another company?

Cannabinoid Biosciences entered a reverse merger agreement with Premier Information Management, Inc. (OTC: PIFR) announced on May 13, 2021, resulting in Cannabinoid Biosciences becoming the operating business of the OTC‑listed entity, with the ticker PIFR and website cbdxfund.com.

Sources

Funding and outcome facts on this page were researched on 2026-08-22 from the pages below.

• Cannabinoid Biosciences, Inc. - LinkedIn
• Cannabinoid Biosciences, Inc. Acquire Controlling Stake of Kid...
• Cannabinoid Biosciences 2025 Company Profile: Valuation, Investors, Acquisition | PitchBook
• Cannabinoid Biosciences, Inc.
• Cannabinoid Biosciences - Torrance, CA
• Cannabinoid Biosciences, Inc.'s Post - LinkedIn
• KDCE - Kid Castle Educational Corp. | Company Profile
• Cannabinoid Biosciences, Inc. (PIFR) Company Information

Cannabinoid Biosciences pitch deck slides

What each slide of the Cannabinoid Biosciences pitch deck says

Slide 2

About Us Cannabinoid Biosciences, Inc. (“CBDZ”) is a biopharmaceutical company, which intends to engage in the discovery, development and commercialization of cures and novel therapeutics derived from: * Proprietary Cannabinoid » Cannabidiol, Endocannabinoids * Phytocannabinoids + Synthetic Cannabinoids product platform suitable for specific treatments in a broad range of disease areas.

Slide 3

Our Business Il Details about our business 0 RESEARCH & DEVELOPMENT Biopharmaceutical R&D and commercialization of cures and novel therapeutics from cannabinoids product formulations for broad range of disease areas. INVESTMENTS & CONSOLIDATION Investments into legalcannabis businesses and deriving value from rollup/consolidation events that leads to IPO in US or Canada FINANCIAL PRODUCTS Financial products in form of asset-backed loans, business property mortgages and other financial products to qualified individuals/businesses in the legal-cannabis businesses Www.CBDXFUND.COM © 00 PROFESSIONAL SERVICES Services include top-level financial reporting, Accounting, SEC Reporting, Business Acq…

Slide 4

Our Market As of November 30, 2018, Thirty-three states and the District of Columbia currently have passed laws and/or regulations that recognize, in one form or another, legitimate medical a= [1 » uses for cannabis and consumer use of cannabis in & = A connection with medical treatment. JT a / TR * The District of Columbia and 10 states -- Alaska, California, TT pr — [4 Colorado, Maine, Massachusetts, Michigan, Nevada, { | | s 4 Oregon, Vermont and Washington -- have adopted the a most expansive laws legalizing marijuana for recreational use. « It is no wonder then that the legal marijuana market in the U.S. is estimated to grow from $9.2 billion in 2017 to $47.3 billion in 2027. « Another…

Slide 5

Regulation The regulatory environment is gradually shifting more ! favorably on medical cannabis biopharmaceutical 8, 7 cannabinoid at both federal and state level. y 8 % « For example, the H.R. 2, the Agriculture Improvement % ida, | Act of 2018, also known as the 2018 Farm Bill, H.R. 2 «iy | includes a provision that lift the ban on hemp, 1, authorize hemp production and research and amend 4 the Controlled Substances Act. See. Z https://rules.house.gov/bill/115/hr-2. « On December 12, 2018, U.S. Congress approved a Bill to Make CBD Federally Legal. Passage of 2018 Farm Bill clarifies CBD legal status and lets U.S. farmers grow hemp, but some regulatory questions remain. Www.CBDXFUND.COM

Slide 6

Competition Competition in Cannabis Industry Right now there is no fund focused on rollup of existing highmargin dispensaries California and across the U.S. marketplace. In California for example, with 358 licensed recreational marijuana stores, the state's three licensing authorities have issued over 5,000 commercial cannabis licenses. So competition is not an issue now. » There is excitement in the air as market sentiment among investors and companies alike in the legal marijuana industry grows more positive. Many states are promising to deliver new markets, reducing risk exposure from the federal government legally intervening. This situation is creating an inviting paradigm for investor…

Slide text above is read directly from the Cannabinoid Biosciences deck PDF embedded on this page.

Related fundraising guides (24)

• Heali Pitch Deck Teardown: Leveraging Clinical Validation to Secure a $3M Seed Round
• Clutch Wallet Pitch Deck Teardown: A $800k Pre-Seed Bet on Web3 Inclusivity
• Yuzu Health Pitch Deck Teardown: A Masterclass in Market Education and Infrastructure Replacement
• Comprehensive Pitch Deck Teardown: A Masterclass in Founder-Market Fit and Category Creation
• Trash Warrior Pitch Deck Teardown: Disrupting the $56B Commercial Waste Collection Market
• Condense Pitch Deck Teardown: Solving the 'Pre-Recorded' Problem in Metaverse Live Events
• Odeko Pitch Deck Teardown: A Masterclass in Obfuscating Real Traction Numbers
• Covey Pitch Deck Teardown: Decentralizing Asset Management via Immutable Track Records
• Yalo Pitch Deck Teardown: Dominating Enterprise Conversational AI via WhatsApp
• Dalan Animal Health Pitch Deck Teardown: A $3.5M Seed for the First Honeybee Vaccine
• Swipes Pitch Deck Teardown: A Minimalist Approach to Productivity Fundraising
• Dame Pitch Deck Teardown: A $7M Series A Masterclass in Normalizing Stigmatized Consumer Goods
• Moonlight Pitch Deck Teardown: A Community-First Approach to Remote Engineering
• Depict.ai Pitch Deck Teardown: A Masterclass in Traction-First Seed Fundraising
• Connected Analytics Pitch Deck Teardown: Solving the Cash-Loyalty Gap in Africa
• ElasticStage Pitch Deck Teardown: Solving the 12-Month Vinyl Supply Chain Bottleneck
• Orchid Pitch Deck Teardown: A Masterclass in High-Stakes Clinical Validation
• Eliyan Pitch Deck Teardown: Solving the Chiplet Interconnect Bottleneck for AI
• Kinnu Pitch Deck Teardown: A Masterclass in Social Proof and Product-Led Growth
• EnergyX Pitch Deck Teardown: A Masterclass in Industrial Validation and Scientific Pedigree
• 10KC Pitch Deck Teardown: A $56M Growth Round Built on Enterprise Social Proof
• Equinom Pitch Deck Teardown: Solving the 250% Plant-Based Cost Gap Through Seed Genetics
• Aceiss Pitch Deck Teardown: A Masterclass in Team Credibility and Problem Framing
• Factorial Pitch Deck Teardown: A Narrative-Driven Series C Strategy for HR Tech

Browse companies alphabetically (1)

• Pitch decks from companies starting with C

More pitch deck teardowns (16)

• Waveborn Pitch Deck Teardown: A CEO's Tactical Guide to Crowdfunding and Early Capital
• Georgiamune Pitch Deck Teardown: A $75M Series A Masterclass in Biotech Pipeline Strategy
• German Garden Restaurant Pitch Deck Teardown: A $15 Million Request for a 2-Year Pop-Up
• Gestoos Pitch Deck Breakdown: A Visual-First Approach to Computer Vision Fundraising
• GetAccept Pitch Deck Breakdown: Dominating the SMB Sales Enablement Category
• Get A Drive Pitch Deck Teardown: A Peer-to-Peer Car-Sharing Concept
• GetEchoed Pitch Deck Teardown: A Community-Driven Approach to Personal Goal Achievement
• Get Groomed Pitch Deck Teardown: A Hyper-Local Marketplace for On-Demand Barbering
• Get Into Nuclear Pitch Deck Teardown: A Niche Directory Facing Massive Content Omissions
• Get Lighthouse Pitch Deck Breakdown: A Minimalist Approach to Management Software
• GetLinks Pitch Deck Breakdown: A Masterclass in Traction-First Storytelling
• Get on Board Pitch Deck Breakdown: Leveraging Data to Unify the Latin American Tech Market
• Getpark Pitch Deck Teardown: A Lean Approach to Private Parking Monetization
• G gate Pitch Deck Teardown: A Hyper-Local Marketing Play for the Singaporean Retail Market
• Ggw timebank Pitch Deck Teardown: A Community-Focused Social Enterprise Vision
• GH Mobil Pitch Deck Teardown: A Mission-Driven Mobile Mechanic Model

Recently published pitch deck teardowns (12)

• Double Pitch Deck Breakdown: Scaling Executive Efficiency with Managed Human Support
• Dwolla Pitch Deck Breakdown
• Elisity Pitch Deck Breakdown: A Masterclass in Selling Enterprise Security to Technical VCs
• emocha health Pitch Deck Breakdown: Proving Clinical Efficacy in Medication Adherence
• elopage Pitch Deck Breakdown: Scaling the Creator Economy's All-in-One Infrastructure
• ElWafeyat Pitch Deck Breakdown: Digitizing the Middle Eastern Death Care Market
• eino Pitch Deck Breakdown: Solving the $65 Billion Waste in Telecom Network Upgrades
• Edfa3fly Pitch Deck Breakdown: A Masterclass in Visual Traction and Market Specificity
• emplu Pitch Deck Breakdown: A Visual-First Approach to the German Employee Benefits Market
• Elioplus Pitch Deck Breakdown: Growth Without a Match
• Equals Pitch Deck Breakdown: A $16M Series A Masterclass in Product-Led Narrative
• Ensembl Pitch Deck Breakdown: A Masterclass in Premium DTC Product Positioning

Fundraising library · Pitch deck examples · Investor directory · Founder database